Associate
During law school, Megan completed a certificate program focused on advising biology Ph.D. students on intellectual property matters, including patentability, freedom-to-operate, and obtaining protection for their technologies. The program also involved analyzing the commercialization of the researchers' innovative technologies. Megan also worked as an analyst for an angel investing group that evaluates startup companies for investment potential, including the strength of their patent portfolios.
While completing her undergraduate degrees, Megan worked in a prosthetics and orthotics lab, which allowed her to gain experience with the fabrication of various medical devices. Megan manages the Drugs section of the firm's IP FDA blog, where she identifies topics for blog posts and assists in editing and coordinating the publication of these posts. She has used her knowledge of the Food & Drug Administration and Orange Book procedures to assist in client counseling regarding these topics.
Megan has a passion for pro bono work. While in law school, she worked with the Health Law Partnership, a branch of Atlanta Legal Aid that partners with impoverished families and children who are patients at Children's Healthcare of Atlanta. Her work with these families included addressing landlord/tenant issues, Supplemental Security Income (SSI), disability, and family law matters. As a summer associate at Finnegan, Megan wrote a brief to file with the U.S. Court of Appeals for Veterans Claims on behalf of an injured veteran. She continues to successfully represent injured veterans as an associate with the firm.
IP FDA Blog
FDA Draft Guidance on Drug-Drug Interaction Assessment for Therapeutic Proteins FDA Draft Guidance on Drug-Drug Interaction Assessment for Therapeutic Proteins
August 21, 2020
Webinar
Protecting Privileged Information in Life Sciences Patent Cases Protecting Privileged Information in Life Sciences Patent Cases
April 16, 2020
Webinar
Webinar
Trade Secrets in the Pharmaceutical Industry Trade Secrets in the Pharmaceutical Industry
October 29, 2019
Webinar
Federal Circuit IP Blog
35 U.S.C. § 314(d) Prevents Appeal of PTAB’s Decision to Deny Institution Upon Reconsideration 35 U.S.C. § 314(d) Prevents Appeal of PTAB’s Decision to Deny Institution Upon Reconsideration
September 10, 2019
IP FDA Blog
FDA Final Guidance on Submitting an ANDA or a 505(b)(2) FDA Final Guidance on Submitting an ANDA or a 505(b)(2)
May 14, 2019
Conference
American Chemical Society National Meeting: Chemistry for New Frontiers American Chemical Society National Meeting: Chemistry for New Frontiers
March 31-April 4, 2019
Orlando
Due to international data regulations, we’ve recently updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.